Puma Biotechnology (PBYI) Cost of Revenue (2017 - 2026)

Puma Biotechnology's Cost of Revenue history runs 10 years deep, the most recent figure standing at $10.4 million for Q1 2026.

• Quarterly Cost of Revenue fell 1.25% year-over-year to $10.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.0 million (down 9.66% YoY) and the FY2025 annual result came in at $58.2 million, down 9.7% from the prior year.
• Cost of Revenue was $10.4 million for Q1 2026 at Puma Biotechnology, down from $23.1 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $29.1 million in Q3 2024 and bottomed at $10.4 million in Q1 2026.
• A 5-year average of $14.8 million and a median of $12.5 million in 2022 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2022 — Cost of Revenue tumbled 63.31% — and 2024, when it surged 119.04%.
• Puma Biotechnology's Cost of Revenue stood at $16.8 million in 2022, then jumped by 44.47% to $24.3 million in 2023, then slumped by 42.77% to $13.9 million in 2024, then surged by 66.13% to $23.1 million in 2025, then tumbled by 54.93% to $10.4 million in 2026.
• Business Quant data shows PBYI's Cost of Revenue at $10.4 million in Q1 2026, $23.1 million in Q4 2025, and $12.2 million in Q3 2025.